Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

CCO Independent Conference Highlights of the European Hematology Association 2022 Congress
  • CME

St├ęphane de Botton, MD
Jesus San-Miguel, MD, PhD
Alessandra Tedeschi, MD
Released: September 6, 2022
Back Next

References

  1. Eichhorst B, Niemann C, Kater A, et al. Time-limited venetoclax-obinutuzumab +/- ibrutinib is superior to chemoimmunotherapy in frontline chronic lymphocytic leukemia (CLL): PFS co-primary endpoint of the randomized phase 3 GAIA/CLL13 trial. Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract LB2365
  2. Eichhorst B, Niemann C, Kater AP, et al. A randomized phase III study of venetoclax-based time-limited combination treatments (RVe, GVe, GIVe) vs standard chemoimmunotherapy (CIT: FCR/BR) in frontline chronic lymphocytic leukemia (CLL) of fit patients: first co-primary endpoint analysis of the International Intergroup GAIA (CLL13) trial. Presented at: 63rd American Society of Hematology Annual Meeting and Exposition; December 11-14, 2021. Abstract 71.
  3. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib ± obinutuzumab vs obinutuzumab + chlorambucil in treatment-naive chronic lymphocytic leukemia: 5-year follow-up of ELEVATE-TN. Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract P666.
  4. FDA. Project Orbis: FDA approves acalabrutinib for CLL and SLL. fda.gov/drugs/resources-information-approved-drugs/project-orbis-fda-approves-acalabrutinib-cll-and-sll. Accessed August 16, 2022.
  5. Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzumab versus chlorambucil and obinutuzumab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395:1278-1291.
  6. Tam CS, Quach H, Nicol A, et al. Zanubrutinib (BGB-3111) plus obinutuzumab in patients with chronic lymphocytic leukemia and follicular lymphoma. Blood Adv. 2020;4:4802-4811.
  7. Lujan JV, Lengerke-Diaz PA, Jacobs C, et al. Ibrutinib reduces obinutuzumab infusion-related reactions in patients with chronic lymphocytic leukemia and is associated with changes in plasma cytokine levels. Haematologica. 2020;105:e22-e25.
  8. Zinzani PL, Mayer J, Auer R, et al. Zanubrutinib + obinutuzumab (ZO) vs obinutuzumab (O) monotherapy in patients (pts) with relapsed or refractory (R/R) follicular lymphoma (FL): primary analysis of the phase 2 randomized ROSEWOOD trial. Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract S205.
  9. Dimopoulos M, Opat S, D’sa S, et al. ASPEN: long-term follow-up results of a phase 3 randomized trial of zanubrutinib (zanu) vs ibrutinib (ibr) in patients (pts) with Waldenström macroglobulinemia (WM). Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract P1161.
  10. FDA. FDA approves zanubrutinib for Waldenström’s macroglobulinemia. fda.gov/drugs/resources-information-approved-drugs/fda-approves-zanubrutinib-waldenstroms-macroglobulinemia. Accessed August 16, 2022.
  11. Treon SP, Cao Y, Xu L, et al. Somatic mutations in MYD88 and CXCR4 are determinants of clinical presentation and overall survival in Waldenstrom macroglobulinemia. Blood. 2014;123:2791-2796.
  12. Treon SP, Xu L, Hunter Z. MYD88 mutations and response to ibrutinib in Waldenström's Macroglobulinemia. N Engl J Med. 2015;373:584-586.
  13. Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence. Leukemia. 2019;33:299-312.
  14. Stone RM, Mandrekar SJ, Sanford BL, et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017;377:454-464.
  15. Levis M. Quizartinib for the treatment of FLT3/ITD acute myeloid leukemia. Future Oncol. 2014;10:1571-1579.
  16. Erba H, Montesinos P, Vrhovac R, et al. Quizartinib prolonged survival vs placebo plus intensive induction and consolidation therapy followed by single-agent continuation in patients aged 18-75 years with newly diagnosed FLT3-ITD+ AML. Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract S100.
  17. Solh MM, Solomon SR, Morris LE, et al. Improved post remission survival of non-favorable risk acute myelogenous leukemia (AML) patients following initial remission induction therapy with FLAG+/-idarubicin versus 3 + 7 (anthracycline + cytarabine). Leuk Res. 2020;93:106318.
  18. Russell N, Wilhelm-Benartzi C, Knapper S, et al. A randomised comparison of CPX-351 and FLAG-ida in high-risk acute myeloid leukaemia. Results from the NCRI AML19 trial. Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract S128.
  19. Perrot A, Lauwers-Cances V, Cazaubiel T, et al. Early versus late autologous stem cell transplant in newly diagnosed multiple myeloma: long-term follow-up analysis of the IFM 2009 trial. Presented at: 62nd American Society of Hematology Annual Meeting and Exposition; December 5-8, 2020. Abstract 143.
  20. Richardson PG, Jacobus SJ, Weller EA, et al. Triplet therapy, transplantation, and maintenance until progression in myeloma. N Engl J Med. 2022;387:132-147.
  21. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017;376:1311-1320.
  22. Rodriguez-Otero P, D’Souza A, Reece D, et al. Teclistamab in combination with daratumumab, a novel, immunotherapy-based approach for the treatment of relapsed/refractory multiple myeloma: updated phase 1b results. Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract S188.
  23. Fernández De Larrea C, Gonzalez-Calle V, Oliver-Caldes A, et al. Efficacy and safety of ARI0002h, an academic BCMA-directed CAR-T cell therapy with fractionated initial therapy and booster dose in patients with relapsed/refractory multiple myeloma. Presented at: European Hematology Association Congress 2022; June 9-17, 2022. Abstract S188.
Back Next
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
AstraZeneca
BeiGene, Ltd.
Jazz Pharmaceuticals, Inc.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings